Alexandria E-B Rossheim1, Tina D Cunningham, Pamela S Hair, Tushar Shah, Kenji M Cunnion, Stephanie B Troy. 1. *Division of Infectious Diseases, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA; †Center for Health Analytics and Discovery, Office of Research, Eastern Virginia Medical School, Norfolk, VA; ‡Department of Pediatrics, Eastern Virginia Medical School, Norfolk, VA; §Children's Specialty Group, Norfolk, VA; and ‖Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA.
Abstract
INTRODUCTION: Uncontrolled HIV infection is known to activate the complement system, leading to an increase in chronic inflammation. Whether or not this activation of complement persists and contributes to chronic inflammation in subjects with HIV infection that is well controlled through use of antiretroviral therapy has not been studied. METHODS: We conducted an observational, cross-sectional study using sera from 305 adults with well-controlled HIV infection and 30 healthy controls. Sera was tested for markers of complement activation (C3a and C5a levels), complement function (CH50 assay), and immunoglobulin levels (IgG1-IgG4) as IgG can activate complement. We evaluated the association of well-controlled HIV infection with C3a, C5a, CH50, IgG1-IgG4, and total IgG levels using both univariate and multivariate analyses, controlling for factors such as age, sex, race, comorbidities (including hepatitis C coinfection), smoking status, and statin use. RESULTS: Well-controlled HIV infection was associated with a 54% increase in complement activation as measured by C3a levels compared with healthy controls (P < 0.0001). Hepatitis C coinfection was associated with a further 52% increase in complement activation, as measured by C3a levels, over HIV alone (P = 0.003). CONCLUSION: These results suggest that complement activation may contribute to a proinflammatory state even in well-controlled HIV infection. Furthermore, hepatitis C virus coinfection may be even more proinflammatory, in complement activation, compared with HIV infection alone.
INTRODUCTION: Uncontrolled HIV infection is known to activate the complement system, leading to an increase in chronic inflammation. Whether or not this activation of complement persists and contributes to chronic inflammation in subjects with HIV infection that is well controlled through use of antiretroviral therapy has not been studied. METHODS: We conducted an observational, cross-sectional study using sera from 305 adults with well-controlled HIV infection and 30 healthy controls. Sera was tested for markers of complement activation (C3a and C5a levels), complement function (CH50 assay), and immunoglobulin levels (IgG1-IgG4) as IgG can activate complement. We evaluated the association of well-controlled HIV infection with C3a, C5a, CH50, IgG1-IgG4, and total IgG levels using both univariate and multivariate analyses, controlling for factors such as age, sex, race, comorbidities (including hepatitis C coinfection), smoking status, and statin use. RESULTS: Well-controlled HIV infection was associated with a 54% increase in complement activation as measured by C3a levels compared with healthy controls (P < 0.0001). Hepatitis C coinfection was associated with a further 52% increase in complement activation, as measured by C3a levels, over HIV alone (P = 0.003). CONCLUSION: These results suggest that complement activation may contribute to a proinflammatory state even in well-controlled HIV infection. Furthermore, hepatitis C virus coinfection may be even more proinflammatory, in complement activation, compared with HIV infection alone.
Authors: M Raux; L Finkielsztejn; D Salmon-Céron; H Bouchez; J L Excler; E Dulioust; J M Grouin; D Sicard; C Blondeau Journal: AIDS Res Hum Retroviruses Date: 2000-04-10 Impact factor: 2.205
Authors: C Carini; R Perricone; C Fratazzi; L Fontana; C De Carolis; R D'Amelio; M C Sirianni; F Aiuti Journal: Scand J Immunol Date: 1989-09 Impact factor: 3.487
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Walter S Speidl; Markus Exner; Jasmin Amighi; Stefan P Kastl; Gerlinde Zorn; Gerald Maurer; Oswald Wagner; Kurt Huber; Erich Minar; Johann Wojta; Martin Schillinger Journal: Eur Heart J Date: 2005-05-25 Impact factor: 29.983
Authors: Laura A Sass; Pamela S Hair; Amy M Perkins; Tushar A Shah; Neel K Krishna; Kenji M Cunnion Journal: PLoS One Date: 2015-12-07 Impact factor: 3.240
Authors: Eunice W Nduati; Mathew J Gorman; Yiakon Sein; Tandile Hermanus; Dansu Yuan; Ian Oyaro; Daniel M Muema; Thumbi Ndung'u; Galit Alter; Penny L Moore Journal: AIDS Date: 2021-10-01 Impact factor: 4.177